Junevity
June 18, 2025
Company Presentation
Regenerative Medicine
153B
Junevity is a longevity biotechnology company developing Cell Reset therapeutics, a new class of medicines reversing transcriptional damage with siRNA. Junevity’s RESET platform is the first to use large-scale human data and AI to identify novel transcription factor targets for down regulation. Launched from UCSF in 2023, Junevity’s long-term goal is to bring Cell Reset therapeutics to the world for longer lifespan and healthspan.
Company HQ City:
San Francisco
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
siRNA for Type 2 diabetes and obesity
CEO
John Hoekman, PhD
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
IND
What is your next catalyst (value inflection) update?
Mar 2026
Website
www.junevity.com
Primary Speaker
.png)
)
)
){kind=logo}
){kind=logo}
){kind=logo}